We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CAH expects specialty revenues to surpass $50B in FY26, fueled by distribution and biopharma services.
CAH is expanding its specialty ecosystem through MSOs like Specialty Alliance and the Solaris Health buyout.
Cardinal Health’s (CAH - Free Report) accelerating specialty strategy is increasingly becoming the centerpiece of its earnings expansion story in fiscal 2026. Following a strong first half, the company raised its fiscal 2026 adjusted earnings per share guidance to $10.15-$10.35, implying 23-26% year-over-year EPS growth and reflecting both strong operational execution and continued demand across its pharmaceutical platform.
The momentum is largely driven by Cardinal Health’s Pharmaceutical and Specialty Solutions segment, which continues to benefit from strong demand for brand and specialty drugs as well as improved operational efficiency. Segmental profit growth in the quarter was supported by a favorable product mix and disciplined cost management, allowing operating earnings to rise significantly even as the company continues investing in its growth initiatives.
A key pillar of this strategy is the rapid expansion of Cardinal Health’s specialty ecosystem. Management expects specialty revenues to exceed $50 billion in fiscal 2026, highlighting the scale the company has achieved in this higher-margin segment. This growth is being fueled by a combination of specialty distribution, biopharma services and physician-practice partnerships.
MSO platforms represent a particularly important growth lever. Cardinal Health’s Specialty Alliance and other MSO structures enable it to partner directly with physician practices, strengthening relationships across oncology, autoimmune and urology specialties. The recent acquisition of Solaris Health, a leading urology MSO, further expands the company’s footprint and adds incremental capabilities to its platform.
Upstream, Cardinal Health’s biopharma services business, including the Sonexus patient-support platform and its 3PL infrastructure, is also gaining traction with manufacturers launching specialty therapies. These capabilities help pharmaceutical partners manage patient access and commercialization, reinforcing Cardinal Health’s role across the entire specialty value chain.
The expanding specialty ecosystem, MSO-driven physician engagement and growing biopharma services platform position Cardinal Health to sustain robust earnings momentum. If these initiatives continue to scale as expected, specialty could remain the primary driver pushing EPS growth toward, or potentially beyond, the upper end of its fiscal 2026 outlook.
Peer Updates
The rising demand for specialty solutions along with an attractive margin has also led the other two leading pharmaceutical distributors — McKesson (MCK - Free Report) and Cencora (COR - Free Report) — to expand into this space.
McKesson continues to deepen its specialty strategy as a key earnings driver, particularly through its oncology and multispecialty platforms. It reported double-digit revenue and EPS growth, supported by strong demand across oncology services, biopharma solutions and pharmaceutical distribution.
MCK highlighted that its oncology network now includes about 3,400 providers, reflecting the expanding scale of its specialty ecosystem. The company is also integrating assets, such as Florida Cancer Specialists and PRISM Vision, strengthening provider services and specialty drug distribution.
With specialty distribution volumes and provider solutions driving operating profit growth, McKesson’s oncology and multispecialty platform is emerging as a key contributor to its long-term earnings expansion.
Cencora is similarly leaning into specialty pharmaceuticals and MSO expansion to accelerate earnings growth. COR reported 12% operating income growth and 9% EPS growth in the quarter, driven largely by its U.S. Healthcare Solutions segment and specialty drug demand.
The company recently expanded its MSO footprint through the acquisition of OneOncology, complementing Retina Consultants of America and strengthening its specialty ecosystem. Cencora expects these physician-focused platforms to deepen relationships with biopharma companies and specialty providers.
As specialty innovation and complex therapies grow, Cencora believes these MSO partnerships will enhance distribution volumes, support physicians and create new earnings growth opportunities for it.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have gained 5.2% over the past six months compared with the industry’s 1.4% rise.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 19.45, above the industry average. It is also higher than its five-year median of 13.46. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 25.1% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
Can Specialty Momentum Push CAH's Earnings Growth Beyond 25% in FY26?
Key Takeaways
Cardinal Health’s (CAH - Free Report) accelerating specialty strategy is increasingly becoming the centerpiece of its earnings expansion story in fiscal 2026. Following a strong first half, the company raised its fiscal 2026 adjusted earnings per share guidance to $10.15-$10.35, implying 23-26% year-over-year EPS growth and reflecting both strong operational execution and continued demand across its pharmaceutical platform.
The momentum is largely driven by Cardinal Health’s Pharmaceutical and Specialty Solutions segment, which continues to benefit from strong demand for brand and specialty drugs as well as improved operational efficiency. Segmental profit growth in the quarter was supported by a favorable product mix and disciplined cost management, allowing operating earnings to rise significantly even as the company continues investing in its growth initiatives.
A key pillar of this strategy is the rapid expansion of Cardinal Health’s specialty ecosystem. Management expects specialty revenues to exceed $50 billion in fiscal 2026, highlighting the scale the company has achieved in this higher-margin segment. This growth is being fueled by a combination of specialty distribution, biopharma services and physician-practice partnerships.
MSO platforms represent a particularly important growth lever. Cardinal Health’s Specialty Alliance and other MSO structures enable it to partner directly with physician practices, strengthening relationships across oncology, autoimmune and urology specialties. The recent acquisition of Solaris Health, a leading urology MSO, further expands the company’s footprint and adds incremental capabilities to its platform.
Upstream, Cardinal Health’s biopharma services business, including the Sonexus patient-support platform and its 3PL infrastructure, is also gaining traction with manufacturers launching specialty therapies. These capabilities help pharmaceutical partners manage patient access and commercialization, reinforcing Cardinal Health’s role across the entire specialty value chain.
The expanding specialty ecosystem, MSO-driven physician engagement and growing biopharma services platform position Cardinal Health to sustain robust earnings momentum. If these initiatives continue to scale as expected, specialty could remain the primary driver pushing EPS growth toward, or potentially beyond, the upper end of its fiscal 2026 outlook.
Peer Updates
The rising demand for specialty solutions along with an attractive margin has also led the other two leading pharmaceutical distributors — McKesson (MCK - Free Report) and Cencora (COR - Free Report) — to expand into this space.
McKesson continues to deepen its specialty strategy as a key earnings driver, particularly through its oncology and multispecialty platforms. It reported double-digit revenue and EPS growth, supported by strong demand across oncology services, biopharma solutions and pharmaceutical distribution.
MCK highlighted that its oncology network now includes about 3,400 providers, reflecting the expanding scale of its specialty ecosystem. The company is also integrating assets, such as Florida Cancer Specialists and PRISM Vision, strengthening provider services and specialty drug distribution.
With specialty distribution volumes and provider solutions driving operating profit growth, McKesson’s oncology and multispecialty platform is emerging as a key contributor to its long-term earnings expansion.
Cencora is similarly leaning into specialty pharmaceuticals and MSO expansion to accelerate earnings growth. COR reported 12% operating income growth and 9% EPS growth in the quarter, driven largely by its U.S. Healthcare Solutions segment and specialty drug demand.
The company recently expanded its MSO footprint through the acquisition of OneOncology, complementing Retina Consultants of America and strengthening its specialty ecosystem. Cencora expects these physician-focused platforms to deepen relationships with biopharma companies and specialty providers.
As specialty innovation and complex therapies grow, Cencora believes these MSO partnerships will enhance distribution volumes, support physicians and create new earnings growth opportunities for it.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have gained 5.2% over the past six months compared with the industry’s 1.4% rise.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 19.45, above the industry average. It is also higher than its five-year median of 13.46. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 25.1% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.